Document is current
Any future updates will be listed below
-
Authors
Dahl, Iselin T. Syberg
Dhami, Sanpreet K. G.
de Sousa, Diana Aguiar
Nakken, Ola
Zarnovicky, Svetozar
Faiz, Kashif Waqar
Sandset, Else Charlotte
Vetvik, Kjersti Grøtta
Kristoffersen, Espen Saxhaug https://orcid.org/0000-0002-8999-5424
-
Funding
Funding for this research was provided by:
University of Oslo
- License Information
-
More Information
Article History
Received: 10 August 2025
Accepted: 28 January 2026
First Online: 13 February 2026
Declarations
:
: The study received approval from the Regional Committee for Medical Research Ethics South-East Norway (D/10955) and the Data Protection Officer at Akershus University Hospital (2018_021).The requirement for informed consent was waived by the Norwegian Regional committee for medical and health research ethics (South-east D) in compliance with Ethics Committee regulations and Norwegian medical research law. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: ITSD, ESK, SKGD, KWF, ON, SZ, ECS have no conflicts of interests. KGV has no disclosures related with the specific topic, but has received honoraria for lecturing and/or participation in advisory boards from Novartis, TEVA, Roche, Pfizer, Lundbeck, Eli Lilly. DAS has no disclosures related with the specific topic, but has received personal fees from AstraZeneca, Organon, and Johnson & Johnson for advisory board participation, DSMB participation for the SECRET trial (University of British Columbia), and speaking fees from Astrazeneca and Bial.
